Navigation Links
Researchers evaluating food allergy treatment
Date:4/17/2008

Researchers at National Jewish Medical and Research Center are conducting trials to evaluate a method to prevent allergic reactions to food. They are feeding peanut- and egg-allergic people increasing doses of an investigational protein extract from the foods to see if they can induce the participants immune systems to tolerate the food.

We hope these trials will lead to the development of the first active, preventive treatment for food allergies, said pediatric allergist David Fleischer, MD, principal investigator for the National Jewish studies. If successful, it would offer great hope for allergic patients and their families, whose lives are haunted by a daily fear of food.

Currently the only advice doctors can give to the estimated 12 million Americans who have food allergies is to avoid the food and carry a self-injectable dose of epinephrine in case they accidentally consume the allergenic food.

There is no treatment available to prevent an allergic reaction to food other than strict avoidance of that food. It can often be difficult to determine if a food contains peanuts or eggs, especially when eating at a restaurant or food prepared by another person. It can even be difficult recognizing egg and peanut proteins listed on food ingredient labels, especially from products that are not manufactured in the U.S.

As a result, thousands of people rush to emergency rooms every year suffering severe allergic reactions to food. As many as 200 people die from allergic reactions to food each year.

Allergists treating hay fever and other allergies have long used immunotherapy, also known as allergy shots, to reduce their patients sensitivity to pollen, cat and dog dander, and dust mites. However, it is not considered safe to give allergy shots to food-allergic patients because the shots can cause severe allergic reactions.

Previous research has suggested that placing the allergenic food protein under the tongue or directly swallowing it, are safer methods of administering food immunotherapy. So that is how National Jewish researchers will try to desensitize allergic patients in the trials.

Study participants (ages 12-40 years for peanut allergy and 6-18 years for egg allergy) will start by consuming tiny amounts of either egg or peanut protein. Physicians and staff at National Jewish will observe them closely to see if they have any symptoms of an allergic reaction. Over the course of several months, participants will consume the protein daily at home, coming in every couple of weeks or so to slowly ramp up the amount of protein they consume until they reach a maintenance dose.

Shortly after reaching the maintenance dose, participants will be tested with a larger amount of either egg or peanut to see if the immunotherapy has reduced the immune systems response. Participants will continue taking the maintenance doses for one to three years to see if they can achieve long-term results. Six to eight weeks after discontinuing the immunotherapy, participants will again consume a larger amount of peanut or egg to see if they have become tolerant of the food.

In traditional immunotherapy, the majority of hay fever patients achieve tolerance, which can last for years, said Dr. Fleischer, the principal investigator for the National Jewish study. We hope to achieve similar results for our food allergic patients.


'/>"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
Source:Eurekalert

Related medicine news :

1. U of M researchers identify process that may help treat Parkinsons, spinal cord injuries
2. OHSU Cancer Institute researchers discover key gene involvement in cancer development
3. Combining liver cancer treatments doubles survival rates, UVA researchers find
4. Leading HIV researchers to collaborate on vaccine development
5. Georgetown researchers find stem cell marker controls 2 key cancer pathways
6. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
7. OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer
8. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
9. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
10. Researchers find disparities in depression among older Hispanics in US
11. Researchers Identify New Genetic Links to Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... Los Angeles, CA (PRWEB) , ... July 24, 2017 , ... ... that will spotlight doctors and the cosmetic surgeries they perform on a daily basis. ... in performing the cosmetic surgery procedures they specialize in at their practices. , ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor ... neurological condition called essential tremor (ET). The seminar will take place on Saturday, Aug. ... Blvd., Independence, OH. The program will run from 9 a.m. to 12 p.m., with ...
(Date:7/24/2017)... ... ... people are taking more steps to protect themselves from sunburn, half of all adults and ... the past year. It’s common and people have been dealing with them since the dawn ... conscientious of the risks that accompany sunburns. , The team at AloeVera.com , a ...
(Date:7/24/2017)... ... 24, 2017 , ... A new report released today by ... sleep health care at scale, indicates record-breaking adherence results for the company’s obstructive ... airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/1/2017)... , June 30, 2017 Zimmer Biomet Holdings, Inc. ... and earnings conference call will be broadcast live over the ... Time.  A news release detailing the quarterly results will be ... the conference call. The live audio webcast can ... http://investor.zimmerbiomet.com . It will be archived for replay following the ...
Breaking Medicine Technology: